NewLimit Raises $435M to Push AI-Designed Age-Reversal Medicine Toward Its First Human Trial

A biotech betting that aging can be reprogrammed at the cellular level just got one of the largest war chests in the longevity field. NewLimit, the South San Francisco startup co-founded by Coinbase chief executive Brian Armstrong, announced on June 2 that it had closed a $435 million Series C, a raise that roughly triples its valuation to about $3.1 billion and clears the way for its first medicine to enter human clinical trials next year.

The round was led by Founders Fund, the Silicon Valley firm co-founded by Peter Thiel, and drew a roster of new and returning investors that reads like a who's-who of tech and biotech capital. New backers include Thrive Capital, Greenoaks, and Quiet Capital. Returning investors include Kleiner Perkins, Abstract, the partnership of Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital, among others.

NewLimit's pitch is built on a once-heretical premise: that biological age is not a one-way ratchet but something pliable, editable, even reversible. "Defying prior dogma, this emerging science has demonstrated that aging is plastic at the cellular level," co-founder and CEO Jacob Kimmel wrote in announcing the round. The company's medicines aim to restore youthful function to old cells through epigenetic reprogramming, a technique that resets how genes are switched on and off without rewriting the underlying DNA.

How AI got the company to the clinic faster than planned

What makes this raise notable for an AI-focused readership is not just the dollar figure but how NewLimit says it got here. The company describes itself as having spent its early years building "the artificial intelligence and genomics technology necessary to discover age reprogramming medicines," then deploying those tools across therapeutic programs spanning metabolic, vascular, and immune health.

That machine-learning-driven search has, by the company's account, paid off ahead of schedule. NewLimit's first candidate targets the liver, and according to Kimmel, the prototype "reverses cell age in old human liver cells." The therapy is designed to help livers "heal faster after injury, avoid damage from dietary challenges, and accelerate recovery from alcohol consumption."

The timeline compression is striking. "We initially believed it would take more than a decade to bring one of these products into human trials," Kimmel wrote. "Based on our recent scientific results, we've accelerated our timelines and plan to initiate our first human trial next year." NewLimit was founded in 2021 by Armstrong, former GV partner and bioengineer Blake Byers, and Kimmel, a stem cell biologist who serves as CEO and president.

The Series C also caps an unusually rapid fundraising cadence. As STAT News reported, this is the third financing NewLimit has announced in roughly a year, following a $130 million Series B in May 2025 and another $45 million in October. The company has, in the words of STAT's Allison DeAngelis, "been moving rapidly, and grabbing investors' attention."

Why it matters

The NewLimit round is one of the clearest signals yet that the "AI for biology" thesis is migrating from drug-discovery infrastructure into capital-intensive, clinic-bound therapeutics, and that investors are willing to underwrite it at multibillion-dollar valuations.

Cellular reprogramming sits at the speculative frontier of medicine. The underlying science traces to Shinya Yamanaka's Nobel-winning discovery that mature cells can be rolled back to a more youthful, stem-cell-like state. The hard problem has always been control: reprogramming cells too far turns them cancerous or erases their identity, while doing it precisely enough to rejuvenate tissue without those failure modes has been beyond reach. This is exactly the kind of high-dimensional search problem where machine learning is supposed to earn its keep, sifting combinations of reprogramming factors and predicting which interventions restore youthful gene expression without tipping cells into chaos.

If NewLimit's AI-led approach genuinely shaved years off a decade-long timeline, that is a meaningful proof point for the broader argument that computational models can accelerate not just target identification but the design of living therapeutics. It also raises the stakes. Algorithmic confidence in a lab dish is one thing; an aging-reversal drug working safely in a human liver is another, and the gap between the two is where most longevity ventures have historically stalled.

There is a governance dimension worth flagging too. The same week, STAT noted, "AI titans" were pressing Congress over DNA safeguards, a reminder that as AI-designed biology moves toward the clinic, the regulatory and biosecurity conversation is racing to keep pace with the capital.

What to watch

The single most important milestone is the liver trial slated for next year. Watch for a confirmed Investigational New Drug filing and a registered trial, which will turn the company's AI-derived claims into measurable clinical endpoints. Beyond that first program, NewLimit says it intends to "add new therapeutic programs and bring a diverse portfolio of therapies into the clinic" over the coming years, so the breadth and pace of its pipeline will test whether its discovery engine is repeatable or a one-off.

Also worth tracking: whether the $3.1 billion valuation holds up against clinical data, how regulators approach an explicitly age-reversal indication that does not map neatly onto existing disease categories, and whether rival longevity and AI-bio startups can raise at comparable scale. With Founders Fund, Thrive, and Eli Lilly Ventures now on the cap table, NewLimit has the runway. The science will decide whether longevity's biggest bet pays off.